Showing results (111-120 of 3,716) with videos related to

Sort By:
Pageof 372
Investigational New Drugs|November 9, 2019
The influence of direct-acting antivirals in hepatitis C virus related hepatocellular carcinoma after curative treatmentYuan-Hung Kuo, Jing-Houng Wang, Kuo-Chin Chang, et al.
Investigational New Drugs|November 11, 2019
A phase 1 dose-escalation study of checkpoint kinase 1 (CHK1) inhibitor prexasertib in combination with p38 mitogen-activated protein kinase (p38 MAPK) inhibitor ralimetinib in patients with advanced or metastatic cancerJohanna C Bendell, Helge G Bischoff, Jimmy Hwang, et al.
Investigational New Drugs|February 2, 2019
Lopinavir-NO, a nitric oxide-releasing HIV protease inhibitor, suppresses the growth of melanoma cells in vitro and in vivoSvetlana Paskas, Emanuela Mazzon, Maria Sofia Basile, et al.
Investigational New Drugs|November 24, 2019
Therapeutic efficacy and imaging assessment of the HER2-targeting chemotherapy drug ZHER2:V2-pemetrexed in lung adenocarcinoma XenograftsJingya Han, Yan Zhao, Xinming Zhao, et al.
Investigational New Drugs|November 26, 2019
Factors affecting symptom presentation in an early-phase clinical trials clinic patient populationGoldy C George, Tito R Mendoza, Eucharia C Iwuanyanwu, et al.
Investigational New Drugs|February 17, 2020
Anticancer activity of Turkish marine extracts: a purple sponge extract induces apoptosis with multitarget kinase inhibition activityHalil I Ciftci, Mustafa Can, Doha E Ellakwa, et al.
Investigational New Drugs|February 10, 2020
Mirtazapine, a dopamine receptor inhibitor, as a secondary prophylactic for delayed nausea and vomiting following highly emetogenic chemotherapy: an open label, randomized, multicenter phase III trialJun Cao, Quchang Ouyang, Shusen Wang, et al.
Investigational New Drugs|September 1, 1988
Evaluation of cardiotoxicity of a new anthracycline derivative: 4'-deoxy-4'-iodo-doxorubicinF Villani, M Galimberti, E Lanza, et al.
Investigational New Drugs|September 1, 1988
Phase I--preliminary phase II trial of iproplatin, a cisplatin analogueF P Paolozzi, R Gaver, B J Poiesz, et al.
Investigational New Drugs|September 1, 1988
A phase II evaluation of cisplatin in unresectable diffuse malignant mesothelioma: a Southwest Oncology Group StudyB L Zidar, S Green, H I Pierce, et al.
Pageof 372